{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:55:42Z","timestamp":1790621742768,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable inherited mucocutaneous fragility disorder characterized by recurrent blisters, erosions, and wounds. Continuous blistering triggers overlapping cycles of never-ending healing and scarring commonly evolving to chronic systemic inflammation and fibrosis. The systemic treatment with allogeneic mesenchymal cells (MSC) from bone marrow has previously shown benefits in RDEB. MSC from adipose tissue (ADMSC) are easier to isolate. This is the first report on the use of systemic allogeneic ADMSC, correlating the clinical, inflammatory, and immunologic outcomes in RDEB indicating long-lasting benefits. We present the case of an RDEB patient harboring heterozygous biallelic<jats:italic>COL7A1<\/jats:italic>gene mutations and with a diminished expression of C7. The patient presented with long-lasting refractory and painful oral ulcers distressing her quality of life. Histamine receptor antagonists, opioid analgesics, proton-pump inhibitors, and low-dose tricyclic antidepressants barely improved gastric symptoms, pain, and pruritus. Concomitantly, allogeneic ADMSC were provided as three separate intravenous injections of 10<jats:sup>6<\/jats:sup>cells\/kg every 21 days. ADMSC treatment was well-tolerated. Improvements in wound healing, itch, pain and quality of life were observed, maximally at 6\u20139 months post-treatment, with the relief of symptoms still noticeable for up to 2 years. Remarkably, significant modifications in PBL participating in both the innate and adaptive responses, alongside regulation of levels of profibrotic factors, MCP-1\/CCL2 and TGF-\u03b2, correlated with the health improvement. This treatment might represent an alternative for non-responding patients to conventional management. It seems critical to elucidate the paracrine modulation of the immune system by MSC for their rational use in regenerative\/immunoregulatory therapies.<\/jats:p>","DOI":"10.3389\/fmed.2020.576558","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T08:19:22Z","timestamp":1606378762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report"],"prefix":"10.3389","volume":"7","author":[{"given":"Roc\u00edo","family":"Maseda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00ednez-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Saced\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Butta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen de","family":"Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garc\u00eda-Barcenilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Illera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"P\u00e9rez-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Melen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Esc\u00e1mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.det.2009.10.011","article-title":"Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa","volume":"28","author":"Chung","year":"2010","journal-title":"Dermatol Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2017.01.002","article-title":"Stromal microenvironment in type VII collagen-deficient skin: the ground for squamous cell carcinoma development","volume":"63","author":"Guerra","year":"2017","journal-title":"Matrix Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1172\/jci68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"E705","DOI":"10.1073\/pnas.1709111115","article-title":"Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa","volume":"115","author":"Nystr\u00f6m","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s12094-019-02073-3","article-title":"Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain","volume":"21","author":"Castelo","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjd.17698","article-title":"Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses","volume":"181","author":"Chac\u00f3n-Solano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am J Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","article-title":"Molecular therapeutics in development for epidermolysis bullosa: update 2020","volume":"24","author":"Has","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic Epidermolysis Bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2019.04.002","article-title":"The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine","volume":"46","author":"Praveen Kumar","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3727\/096368913x667709","article-title":"Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives","volume":"23","author":"Liang","year":"2014","journal-title":"Cell Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"394917","DOI":"10.1155\/2015\/394917","article-title":"Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications","volume":"2015","author":"Castro-Manrreza","year":"2015","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/emm.2013.94","article-title":"Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp Mol Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cyto.a.23242","article-title":"Isolation, cultivation, and characterization of human mesenchymal stem cells","volume":"93","author":"Mushahary","year":"2018","journal-title":"Cytometry A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1089\/scd.2011.0722","article-title":"Same or not the same? Comparison of adipose tissue-derived vs. bone marrow-derived mesenchymal stem and stromal cells","volume":"21","author":"Strioga","year":"2012","journal-title":"Stem Cells Dev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2133.2010.09713.x","article-title":"The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation","volume":"163","author":"Esc\u00e1mez","year":"2010","journal-title":"Br J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.18128","article-title":"Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa","volume":"182","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ad.2017.08.008","article-title":"Genetic diagnosis of epidermolysis bullosa: recommendations from an expert Spanish research group","volume":"109","author":"S\u00e1nchez-Jimeno","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcyt.2018.09.003","article-title":"Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile","volume":"20","author":"\u00c1lvarez-Fuente","year":"2018","journal-title":"Cytotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-9-76","article-title":"Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa","volume":"9","author":"El Hachem","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1750-1172-8-81","article-title":"Beh\u00e7et's disease: new insight into the relationship between procoagulant state, endothelial activation\/damage and disease activity","volume":"8","author":"Fern\u00e1ndez-Bello","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","article-title":"The birmingham epidermolysis bullosa severity score: development and validation","volume":"160","author":"Moss","year":"2009","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.burns.2011.04.007","article-title":"Measurement of itching: validation of the Leuven Itch Scale","volume":"37","author":"Haest","year":"2011","journal-title":"Burns"},{"key":"B31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.burns.2012.11.011","article-title":"Spanish transcultural adaptation of the Leuven Itch Scale","volume":"39","author":"Yuste","year":"2013","journal-title":"Burns"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.pain.2011.07.005","article-title":"Validity of four pain intensity rating scales","volume":"152","author":"Ferreira-Valente","year":"2011","journal-title":"Pain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4097\/kjae.2017.70.4.407","article-title":"Statistical data preparation: management of missing values and outliers","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1517\/14712598.2010.519333","article-title":"Mesenchymal stem cells: biological properties and clinical applications","volume":"10","author":"Garc\u00eda-G\u00f3mez","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2009.11.007","article-title":"Diversity in T cell memory: an embarrassment of riches","volume":"31","author":"Jameson","year":"2009","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1196\/annals.1443.011","article-title":"Basic and clinical immunology of Siglecs","volume":"1143","author":"von Gunten","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2230.2011.04091.x","article-title":"The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: proceedings of a multidisciplinary team study day","volume":"36","author":"Hubbard","year":"2011","journal-title":"Clin Exp Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/bjd.18475","article-title":"Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study","volume":"182","author":"Reimer","year":"2020","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clnu.2019.02.023","article-title":"A nutrition-based approach to epidermolysis bullosa: causes, assessments, requirements and management","volume":"39","author":"Salera","year":"2020","journal-title":"Clin Nutr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/jid.2014.500","article-title":"Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa","volume":"135","author":"Mack","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/brain\/awx069","article-title":"Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy","volume":"140","author":"von Bischhoffshausen","year":"2017","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/pde.12486","article-title":"Evaluation of treatments for pruritus in epidermolysis bullosa","volume":"32","author":"Danial","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.12885","article-title":"Burden of itch in epidermolysis bullosa","volume":"171","author":"Snauwaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2340\/00015555-0376","article-title":"Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews","volume":"88","author":"van Scheppingen","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS ONE"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1574888x13666180913123424","article-title":"The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review","volume":"14","author":"Golchin","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jcyt.2016.07.006","article-title":"Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor","volume":"18","author":"Valencia","year":"2016","journal-title":"Cytotherapy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2541275","DOI":"10.1155\/2017\/2541275","article-title":"Human adipose-derived stem cells exhibit enhanced proliferative capacity and retain multipotency longer than donor-matched bone marrow mesenchymal stem cells during expansion in vitro","volume":"2017","author":"Burrow","year":"2017","journal-title":"Stem Cells Int"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cells8101160","article-title":"Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives","volume":"8","author":"Coppin","year":"2019","journal-title":"Cells."},{"key":"B54","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2450\/2012.0171-12","article-title":"The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro","volume":"11","author":"Schlimp","year":"2013","journal-title":"Blood Transfus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1213\/ANE.0b013e31824724c8","article-title":"Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry","volume":"114","author":"Solomon","year":"2012","journal-title":"Anesth Analg"},{"key":"B56","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.13953","article-title":"The epidermolysis bullosa disease activity and scarring index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa","volume":"31","author":"Jain","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1097\/md.0000000000001528","article-title":"Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa","volume":"94","author":"Annicchiarico","year":"2015","journal-title":"Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/ijms17101625","article-title":"Autoimmunity and cytokine imbalance in inherited epidermolysis bullosa","volume":"17","author":"Esposito","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B61","first-page":"340","article-title":"IL-6\/IL-10 Ratio as a prognostic and predictive marker of the severity of inherited epidermolysis bullosa","volume":"14","author":"Tampoia","year":"2017","journal-title":"Iran J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1750-1172-8-132","article-title":"Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa","volume":"8","author":"Tampoia","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.jid.2018.03.768","article-title":"758 Autoantibodies in epidermolysis bullosa","volume":"138","author":"Gostynski","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.4049\/jimmunol.155.7.3322","article-title":"Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets","volume":"155","author":"Brinkmann","year":"1995","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.4049\/jimmunol.166.10.6000","article-title":"Histamine induces CD86 expression and chemokine production by human immature dendritic cells","volume":"166","author":"Caron","year":"2001","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1084\/jem.20180595","article-title":"Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses","volume":"216","author":"Franco","year":"2019","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"17779","DOI":"10.1074\/jbc.271.30.17779","article-title":"Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors","volume":"271","author":"Gharaee-Kermani","year":"1996","journal-title":"J Biol Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/acp-2011-0039","article-title":"TGF\u03b2-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Knaup","year":"2011","journal-title":"Anal Cell Pathol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/msb.2013.17","article-title":"Global remodelling of cellular microenvironment due to loss of collagen VII","volume":"9","author":"K\u00fcttner","year":"2013","journal-title":"Mol Syst Biol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"389","DOI":"10.18632\/aging.100755","article-title":"Transcriptome and ultrastructural changes in dystrophic Epidermolysis bullosa resemble skin aging","volume":"7","author":"Breitenbach","year":"2015","journal-title":"Aging"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1093\/hmg\/ddu102","article-title":"Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-\u03b2 signalling in modifying disease severity","volume":"23","author":"Odorisio","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/jci34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"461","DOI":"10.14503\/thij-13-3466","article-title":"Inflammation and C-reactive protein in atrial fibrillation: cause or effect?","volume":"41","author":"Galea","year":"2014","journal-title":"Tex Heart Inst J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1378\/chest.13-0693","article-title":"Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations","volume":"144","author":"Shoki","year":"2013","journal-title":"Chest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.lfs.2010.07.012","article-title":"C-reactive protein triggers inflammatory responses partly via TLR4\/IRF3\/NF-\u03baB signaling pathway in rat vascular smooth muscle cells","volume":"87","author":"Liu","year":"2010","journal-title":"Life Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"20190888","DOI":"10.1042\/bsr20190888","article-title":"C-reactive protein promotes inflammation through TLR4\/NF-\u03baB\/TGF-\u03b2 pathway in HL-1 cells","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jid.2017.07.002","article-title":"Pro-inflammatory chemokines and cytokines dominate the blister fluid molecular signature in patients with epidermolysis bullosa and affect leukocyte and stem cell migration","volume":"137","author":"Alexeev","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6901983","DOI":"10.1155\/2018\/6901983","article-title":"Mesenchymal stromal cells and cutaneous wound healing: a comprehensive review of the background, role, and therapeutic potential","volume":"2018","author":"Hu","year":"2018","journal-title":"Stem Cells Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jaut.2017.07.007","article-title":"Modulation of inflammatory and immune responses by vitamin D","volume":"85","author":"Colotta","year":"2017","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.576558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:57:00Z","timestamp":1697245020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.576558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":79,"alternative-id":["10.3389\/fmed.2020.576558"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.576558","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"article-number":"576558"}}